Ticagrelor versus Clopidogrel in Patients with Severe Renal Insufficiency Undergoing PCI for Acute Coronary Syndrome

Table 3

The association between use of different antiplatelet agents and bleeding outcomes using an extended cox model.

Outcome	Events (n)		Nonadjusted model		Model I		Model 2
	Ticagrelor (n = 108)	Clopidogrel (n = 168)	HR (95% CI)	value	HR (95% CI)	value	HR (95% CI)	value
Total BARC bleedings	39 (36.1)	37 (22.0)	1.88 (1.12∼3.15)	0.026	1.96 (1.17∼3.28)	0.021	3.01 (1.81∼5.62)	0.010
BARC 1 or 2 bleedings	25 (23.1)	24 (14.3)	1.83 (0.97∼3.46)	0.064	2.06 (1.08∼3.92)	0.038	3.14 (1.52∼5.76)	0.018
BARC 3 or 5 bleedings	14 (13.0)	13 (7.7)	1.98 (0.83∼4.77)	0.116	1.9 (0.79∼4.56)	0.101	2.87 (1.12∼7.03)	0.045

Notes. data presented are HRs and 95% CIs. Adjust I model adjusts for age and gender; adjust II model adjust for variables that, when added to this model, changed the matched odds ratio by at least 10 percent, including adjusting for adjust I + smoking status, diabetes, diagnosis, congestive heart failure, COPD, stroke history, heart rate, hemoglobin, ejection fraction, hs-cTn T, Nt-proBNP, eGFR, dialysis, GP IIb/IIIa inhibitors, 3-vessel disease.